Sumithra J. Mandrekar

Author

Also Known As

Adjei, Alex A., Oreste E. Salavaggione, S J Mandrekar, S. J. Mandrekar, S. Mandrekar, S.J. Mandrekar, Sumithra J Mandrekar, Sumithra J. Mandrekar, Sumithra Mandrekar

352

Publications

18K

Citations

H-Index

142

Concepts

All Affiliations

Mayo Clinic Mayo Clinic in Arizona Mayo Clinic in Florida University of Chicago Dana-Farber Cancer Institute

About

Sumithra J. Mandrekar is an author at Mayo Clinic specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	18	20	1.1K
2	Engineering	4	4	213
3	Education	1	1	22
4	Law	1	1	1.8K
5	Management	1	1	14

Sumithra J. Mandrekar

129

Publications

13.2K

Citations

H-Index

Page 1

	Year	Citations
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation Richard M. Stone, Sumithra J. Mandrekar, Ben L. Sanford, New England Journal of Medicine	2017	2.1K
RECIST 1.1—Update and clarification: From the RECIST committee Lawrence H. Schwartz, Saskia Litière, Elisabeth G.E. de Vries, European Journal of Cancer Public PolicyRecist 1.1—UpdateLawAdministrative LawPolicy Process	2016	1.8K
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, New England Journal of Medicine	2018	927
CT Screening for Lung Cancer: Five-year Prospective Experience Stephen J. Swensen, James R. Jett, Thomas E. Hartman, Radiology	2005	637
Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges Sumithra J. Mandrekar, Daniel J. Sargent Journal of Clinical Oncology	2009	389
Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials Brian P. Hobbs, Bradley P. Carlin, Sumithra J. Mandrekar, Biometrics	2011	376
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma Martha Q. Lacy, Suzanne R. Hayman, Morie A. Gertz, Journal of Clinical Oncology	2009	320
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease Martha Q. Lacy, Jacob B. Allred, Morie A. Gertz, Blood	2011	221
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) Martha Q. Lacy, Suzanne R. Hayman, Morie A. Gertz, Leukemia Hematological MalignancyOncologyImmunologyHematologyMyeloid Neoplasia	2010	198
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia Konstanze Döhner, Christian Thiede, Nikolaus Jahn, Blood	2019	188

Page 1